Literature DB >> 10471856

Impact of resistant pneumococcus on rates of acute mastoiditis.

P J Antonelli1, N Dhanani, C M Giannoni, P S Kubilis.   

Abstract

OBJECTIVE: To determine whether the rate of acute mastoiditis is rising, specifically as a result of antibiotic-resistant strains of Streptococcus pneumoniae.
METHODS: A retrospective chart review of all patients with a discharge diagnosis of acute mastoiditis between July 1, 1987, and June 30, 1997, was performed at our academic, tertiary-care medical center. There were no interventions, and the main outcome measures included the number of cases of acute or coalescent mastoiditis, stratified by pathogen, per year.
RESULTS: The rate of acute mastoiditis as a proportion of yearly otorhinolaryngology admissions increased linearly over time (P = 0. 024). Pneumococcal-related rates of acute mastoiditis, expressed as a proportion of yearly hospital and otorhinolaryngology admissions, increased linearly over time (P = 0.002, P = 0.002). All but 1 case of pneumococcal mastoiditis during the past 3 years were caused by penicillin-resistant strains.
CONCLUSIONS: The emergence of antibiotic-resistant S pneumoniae may be responsible for an increasing rate of acute mastoiditis.

Entities:  

Mesh:

Year:  1999        PMID: 10471856     DOI: 10.1016/S0194-5998(99)70170-1

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  3 in total

1.  Challenges in the management of acute mastoiditis in children.

Authors:  Sofia Kordeluk; Mordechai Kraus; Eugene Leibovitz
Journal:  Curr Infect Dis Rep       Date:  2015-05       Impact factor: 3.725

2.  Pragmatic randomised controlled trial of two prescribing strategies for childhood acute otitis media.

Authors:  P Little; C Gould; I Williamson; M Moore; G Warner; J Dunleavey
Journal:  BMJ       Date:  2001-02-10

Review 3.  Complications of acute otitis media in children.

Authors:  Kimmo Leskinen
Journal:  Curr Allergy Asthma Rep       Date:  2005-07       Impact factor: 4.919

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.